Hanson S. Gifford III

Hanson is a Managing Partner at The Foundry, LLC, and a Partner at Lightstone Ventures. Since its inception in 1998, Hanson has led The Foundry in the invention, identification, and development of new technologies; the formation, financing, and staffing of the new companies; and ongoing support of these new ventures as a board member. Hanson was also involved in founding five ophthalmology companies at Forsight Labs.

Prior to The Foundry, Hanson was VP of R&D at Heartport- NASDAQ: HPRT. In 1992, Hanson co-founded and served as managing director of Bavaria Medizin Technologie, GmbH. In 1991, Hanson served as President of Cardiovascular Therapeutic Technologies, acquired by Eli Lilly. From 1985-1990, Hanson worked at DVI, also acquired by Eli Lilly. Before joining DVI, Hanson worked in engineering roles at Oximetrix, acquired by Abbott, and General Dynamics.

Hanson serves on the boards of directors of FIRE1, Foundry Therapeutics 2, Half Moon Medical, Tangible Science, Contego, and Reprieve Cardiovascular. At Lightstone Ventures, Hanson is a member of the LSV medical device team. He also serves as a mentor to the Stanford Biodesign fellows. He has a BSME from Cornell University and is a named inventor on over 370 issued US patents.